Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi

Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other anti-amyloid Alzheimer’s disease therapy on the market.